Royal Bank Of Canada Vaxxinity, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$0.62 - $0.86 $603 - $837	974 New	974 $0
Q1 2024 May 15, 2024	SELL	$0.62 - $0.86 $7,926 - $10,994	-12,784 Reduced 92.92%	974 $0
Q4 2023 Feb 14, 2024	BUY	$0.7 - $1.31 $4,179 - $7,820	5,970 Added 76.66%	13,758 $11,000
Q3 2023 Nov 14, 2023	BUY	$1.25 - $3.0 $2,675 - $6,420	2,140 Added 37.89%	7,788 $10,000
Q2 2023 Aug 14, 2023	BUY	$1.73 - $2.79 $9,412 - $15,180	5,441 Added 2628.5%	5,648 $14,000
Q1 2023 May 15, 2023	BUY	$1.43 - $4.24 $296 - $877	207 New	207 $0
Q2 2022 Aug 15, 2022	BUY	$1.55 - $6.95 $1,550 - $6,950	1,000 New	1,000 $2,000

198K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.